Newborns are Exposed to mRNA residues in Mothers Breast Milk. They are Not Approved for Infants Less than 6 Months Old. 2022-12-28. Jorma A. Jyrkkanen

Babies died in Utero post mRNA injection of mothers. More Babies in ICU post Vaccination of Moms. See https://twitter.com/TexasLindsay_/status/1614306700533846016

Its clear that a non approved administration is taking polace via proxy contamination of mothers breast mmilk if she is nursing on the breast. Does this harm the infaants natural immune system development? What is the effect on the childs developing immune system? Does it damamge mitochondrial immune support systems? What does it do to short chain fatty acids in the infants intestinal flora? Is this contamination contributing to the epidemic of respiratory cases ending up in hospitals post Pandemic?

MORE FROM JAMA PEDIATRICS Research Letter September 26, 2022 Detection of Messenger RNA COVID-19 Vaccines in Human Breast Milk Nazeeh Hanna, MD1; Ari Heffes-Doon, MD1; Xinhua Lin, PhD2; et al Claudia Manzano De Mejia, MD2; Bishoy Botros, BS2; Ellen Gurzenda, BS2; Amrita Nayak, MD1 Author Affiliations Article Information JAMA Pediatr. 2022;176(12):1268-1270. doi:10.1001/jamapediatrics.2022.3581 related articles icon Related Articles Correction Errors in Supplement Vaccination is a cornerstone in fighting the COVID-19 pandemic. However, the initial messenger RNA (mRNA) vaccine clinical trials excluded several vulnerable groups, including young children and lactating individuals.1 The US Food and Drug Administration deferred the decision to authorize COVID-19 mRNA vaccines for infants younger than 6 months until more data are available because of the potential priming of the children’s immune responses that may alter their immunity.2 The Centers for Disease Control and Prevention recommends offering the COVID-19 mRNA vaccines to breastfeeding individuals,3 although the possible passage of vaccine mRNAs in breast milk resulting in infants’ exposure at younger than 6 months was not investigated. This study investigated whether the COVID-19 vaccine mRNA can be detected in the expressed breast milk (EBM) of lactating individuals receiving the vaccination within 6 months after delivery. Methods This cohort study included 11 healthy lactating individuals who received either the Moderna mRNA-1273 vaccine (n = 5) or the Pfizer BNT162b2 vaccine (n = 6) within 6 months after delivery (Table 1). Participants were asked to collect and immediately freeze EBM samples at home until transported to the laboratory. Samples of EBM were collected before vaccination (control) and for 5 days postvaccination. A total of 131 EBM samples were collected 1 hour to 5 days after vaccine administration. Extracellular vesicles (EVs) were isolated in EBM using sequential centrifugation, and the EV concentrations were determined by ZetaView (Analytik) (eMethods in the Supplement). The presence of COVID-19 vaccine mRNA in different milk fractions (whole EBM, fat, cells, and supernatant EVs) was assayed using 2-step quantitative reverse transcriptase–polymerase chain reaction. The vaccine detection limit was 1 pg/mL of EBM (eMethods in the Supplement). Results Of 11 lactating individuals enrolled, trace amounts of BNT162b2 and mRNA-1273 COVID-19 mRNA vaccines were detected in 7 samples from 5 different participants at various times up to 45 hours postvaccination (Table 2). The mean (SD) yield of EVs isolated from EBM was 9.110 (5.010) particles/mL, and the mean (SD) particle size was 110.0 (3.0) nm. The vaccine mRNA appears in higher concentrations in the EVs than in whole milk (Table 2). No vaccine mRNA was detected in prevaccination or postvaccination EBM samples beyond 48 hours of collection. Also, no COVID-19 vaccine mRNA was detected in the EBM fat fraction or the EBM cell pellets. Jorma Jyrkkanen Researcher